BioN­Tech nabs up to $90M for mpox vac­cine as it be­gins PhI/II tri­al be­hind Mod­er­na's lead

Build­ing on its in­fec­tious dis­ease work in Covid-19, malar­ia and tu­ber­cu­lo­sis, BioN­Tech is now rolling out a Phase I/II test of a jab to pro­tect against the mpox virus, which caused in­ter­na­tion­al con­cern in the sum­mer of 2022 but has since waned.

Like its Covid-19 vac­cine coun­ter­part Mod­er­na, the Ger­man biotech is hop­ing to cre­ate an mR­NA-based vac­cine for mpox, which can lead to ir­ri­ta­ble skin le­sions, rash­es and painful swelling of the lymph nodes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER